9. Talan DA, Salhi BA, Moran GJ, Mower WR, Hsieh YH, Krishnadasan A, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med 2015;16(1):89–97.
10. Sreeramoju P, Porbandarwalla NS, Arango J, Latham K, Dent DL, Stewart RM, et al. Recurrent skin and soft tissue infections due to methicillin-resistant
Staphylococcus aureus requiring operative debridement. Am J Surg 2011;201(2):216–20.
11. Theocharidis V, Katsaros I, Sgouromallis E, Serifis N, Boikou V, Tasigiorgos S, et al. Current evidence on the role of smoking in plastic surgery elective procedures: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 2018;71(5):624–36.
12. Tran TS, Jamulitrat S, Chongsuvivatwong V, Geater A. Risk factors for postcesarean surgical site infection. Obstet Gynecol 2000;95(3):367–71.
13. Avila C, Bhangoo R, Figueroa R, Santorelli J, Ogburn P, Desan PH. Association of smoking with wound complications after cesarean delivery. J Matern Fetal Neonatal Med 2012;25(8):1250–3.
16. Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant
Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014;20(Suppl 4):3–18.
17. Demling RH, Waterhouse B. The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant
Staphylococcus aureus
. J Burns Wounds 2007;7:e8.
18. Ostojić M, Hukić M. Genotypic and phenotypic characteristics of Methicillin-resistant
Staphylococcus aureus (MRSA) strains, isolated on three different geography locations. Bosn J Basic Med Sci 2015;15(3):48–56.
19. Brink AJ, Richards GA. The role of multidrug and extensive-drug resistant Gam-negative bacteria in skin and soft tissue infections. Curr Opin Infect Dis 2020;33(2):93–100.
20. Jabbour JF, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Curr Opin Infect Dis 2020;33(2):146–54.
22. Al Rahmany D, Albeloushi A, Alreesi I, Alzaabi A, Alreesi M, Pontiggia L, et al. Exploring bacterial resistance in Northern Oman, a foundation for implementing evidence-based antimicrobial stewardship program. Int J Infect Dis 2019;83:77–82.
24. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels (Belgium): International Diabetes Federation; 2019.
25. Nair D, Singapurwala M, Al-Benwan K. Microbiological and clinical characteristics of sternal wound infections following cardiac surgery in a teaching hospital in Kuwait: A 5-year retrospective study. Ann Clin Cardiol 2019;1(1):30–6.
28. Tognetti L, Martinelli C, Berti S, Hercogova J, Lotti T, Leoncini F, et al. Bacterial skin and soft tissue infections: Review of the epidemiology, microbiology, aetiopathogenesis and treatment: A collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol 2012;26(8):931–41.
29. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant
Staphylococcus aureus
. Nat Rev Dis Primers 2018;4:18033.
30. Zigmond J, Pecen L, Hajek P, Raghubir N, Omrani AS. MRSA infection and colonization rates in Africa and the Middle East: a systematic review and meta-analysis. In: 16th International Congress on Infectious Diseases; 2014 April 2–5; Cape Town, South Africa. pp 170.
34. Udo EE, Panigrahi D, Jamsheer AE. Molecular typing of methicillin-resistant
Staphylococcus aureus isolated in a Bahrain hospital. Med Princ Pract 2008;17(4):308–14.
35. Udo EE, Boswihi SS. Antibiotic Resistance Trends in Methicillin-Resistant
Staphylococcus aureus Isolated in Kuwait Hospitals: 2011–2015. Med Princ Pract 2017;26(5):485–90.
37. El-Mahdy TS, El-Ahmady M, Goering RV. Molecular characterization of methicillin-resistant
Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients. Clin Microbiol Infect 2014;20(2):169–73.
38. Matar MJ, Moghnieh R, Alothman AF, Althaqafi AO, Alenazi TH, Farahat FM, et al. Treatment patterns, resource utilization, and outcomes among hospitalized patients with methicillin-resistant
Staphylococcus aureus complicated skin and soft tissue infections in Lebanon and Saudi Arabia. Infect Drug Resist 2017;10:43–8.
39. Mahmood A, Almasrouri M, Hussain A. Prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) and use of tunneled hemodialysis catheters. Qatar Med J 2019;2019(2):86.
41. Udo EE, Al-Lawati BAH, Al-Muharmi Z, Thukral SS. Genotyping of methicillin-resistant
Staphylococcus aureus in the Sultan Qaboos University Hospital, Oman reveals the dominance of Panton-Valentine leucocidin-negative ST6-IV/t304 clone. New Microbes New Infect 2014;2(4):100–5.
42. Udo EE, Boswihi SS, Mathew B, Noronha B, Verghese T, Al-Jemaz A, et al. Emergence of Methicillin-Resistant
Staphylococcus aureus Belonging to Clonal Complex 15 (CC15-MRSA) in Kuwait Hospitals. Infect Drug Resist 2020;13:617–26.
43. Boswihi SS, Udo EE, Al-Sweih N. Shifts in the Clonal Distribution of Methicillin-Resistant
Staphylococcus aureus in Kuwait Hospitals: 1992–2010. PLoS One 2016;11(9):e0162744.
44. Barbier F, Timsit JF. Risk stratification for multidrug-resistant bacteria in patients with skin and soft tissue infection. Curr Opin Infect Dis 2020;33(2):137–45.
45. Shankar C, Pragasam AK, Veeraraghavan B, Amladi A. Bad bug, no test: Tigecycline susceptibility testing challenges and way forward. Indian J Med Microbiol 2019;37(1):91–4.
46. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): Assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013;19(9):E377–85.
47. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant
Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51(2):423–8.
48. Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect 2013;14(3):304–12.
49. Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008;29(2):160–9.
51. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: Does inadequate antibiotic therapy affect patient outcomes? Surg Infect 2009;10(4):323–31.
52. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012;65(2):128–34.
53. Zilberberg MD, Shorr AF, Micek ST, Hoban AP, Pham V, Doherty JA, et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: Implications of healthcare-associated infection risk factors. Infect Control Hosp Epidemiol 2009;30(12):1203–10.
54. Harbarth S. Control of endemic methicillin-resistant
Staphylococcus aureus-recent advances and future challenges. Clin Microbiol Infect 2006;12(12):1154–62.
55. Francois P, Bento M, Renzi G, Harbarth S, Pittet D, Schrenzel J. Evaluation of three molecular assays for rapid identification of methicillin-resistant
Staphylococcus aureus
. J Clin Microbiol 2007;45(6):2011–3.
56. Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C, et al. Universal screening for methicillin-resistant
Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299(10):1149–57.
57. Harbarth S, Hawkey PM, Tenover F, Stefani S, Pantosti A, Struelens MJ. Update on screening and clinical diagnosis of meticillin-resistant
Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2011;37(2):110–7.
58. Montravers P, Snauwaert A, Welsch C. Current guidelines and recommendations for the management of skin and soft tissue infections. Curr Opin Infect Dis 2016;29(2):131–8.
62. Menarini Industrie A. Farmaceutiche, Florence Italy. Delafloxacin [Summary of product characteristics] 2019.
64. Soriano A, Grau S, Rivolo S, Remak E, Peral C, Kantecki M, et al. A cost-minimization model to evaluate the impact of ceftaroline fosamil for the treatment of complicated skin and soft tissue infections in hospitalized adults in Spain. Value Health 2018;21(3):S231.
65. Basilea Medical Ltd [Internet]. Summary of Product Characteristics: Zevtera 500 mg powder for concentrate for solution for infusion Medicines and Healthcare Products Regulatory Agency; [cited 2021 Nov 7]. Available from:
https://www.medicines.org.uk/emc/product/9164#gref
.
68. Howell MD, Davis AM. Management of Sepsis and Septic Shock. JAMA 2017;317(8):847–8.
69. Bassetti M, Guirao X, Montravers P, Rossolini GM, Sánchez García M, Sganga G, et al. Influence of age on the clinical efficacy of tigecycline in severely ill patients. J Glob Antimicrob Resist 2019;18:199–206.
70. Bassetti M, Eckmann C, Peghin M, Carnelutti A, Righi E. When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis 2018;31(2):163–9.
81. Linder KE, Nicolau DP, Nailor MD. Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. Hosp Pract (1995) 2017;45(1):9–15.
82. Eckmann C. The importance of source control in the management of severe skin and soft tissue infections. Curr Opin Infect Dis 2016;29(2):139–44.